Transmedics Group Inc’s recently made public that its Director Basile Edward M unloaded Company’s shares for reported $0.69 million on May 09 ’25. In the deal valued at $115.63 per share,6,000 shares were sold. As a result of this transaction, Basile Edward M now holds 732 shares worth roughly $89377.2.
Then, EDWARD BASILE bought 6,000 shares, generating $693,780 in total proceeds.
Before that, Khayal Tamer I sold 2,407 shares. Transmedics Group Inc shares valued at $183,967 were divested by the Chief Commercial Officer at a price of $76.43 per share. As a result of the transaction, Khayal Tamer I now holds 36,042 shares, worth roughly $4.4 million.
JP Morgan downgraded its Transmedics Group Inc [TMDX] rating to a Neutral from a an Overweight in a research note published on December 17, 2024; the price target was decreased to $75 from $116. A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in late November from “a Buy” to “a Hold”. Oppenheimer also remained covering TMDX and reiterated its “an Outperform” recommendation on October 29, 2024. Needham maintained its rating on October 29, 2024. It rated TMDX as “a Buy”.
Price Performance Review of TMDX
On Monday, Transmedics Group Inc [NASDAQ:TMDX] saw its stock jump 0.43% to $122.10. Over the last five days, the stock has gained 2.84%. Transmedics Group Inc shares have risen nearly 95.83% since the year began. Nevertheless, the stocks have fallen -10.31% over the past one year.
How much short interest is there in Transmedics Group Inc?
A steep rise in short interest was recorded in Transmedics Group Inc stocks on 2025-04-30, dropping by -0.68 million shares to a total of 8.8 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 9.48 million shares. There was a decline of -7.71%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 24, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $200 price target.
